Australia markets open in 1 hour 30 minutes

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.9200-0.0200 (-0.68%)
At close: 04:00PM EST
2.9500 +0.03 (+1.03%)
After hours: 04:29PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.9400
Open3.0400
Bid2.9000 x 3000
Ask2.9900 x 1300
Day's range2.9100 - 3.0599
52-week range1.7100 - 14.4200
Volume385,228
Avg. volume746,238
Market cap243.43M
Beta (5Y monthly)0.64
PE ratio (TTM)N/A
EPS (TTM)-1.5440
Earnings date03 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.75
  • GlobeNewswire

    Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted nine employees nonqualified stock options to purchase an aggregate of 72,300 shares of its common stock with an exercise price of $3.03, which is equal to the closing price of Gritstone’s common stock on November 11, 2022, the date of the grant. These st

  • GlobeNewswire

    Gritstone to Participate in Upcoming Investor Conferences

    EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor conferences. 5th Annual Evercore ISI HealthCONx ConferenceFireside Chat Date and Time: Tuesday, November 29, 2022 at 10:30am ESTPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive OfficerLocati

  • GlobeNewswire

    Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022

    -- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months – median not yet reached -- -- Patients who achieve a molecular response include those with liver metastasis and are not enriched for baseline PD-L1 expression, high tumor mutation burden or IFNg-related genes -- EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS